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Objective To compare the characteristics and
outcomes of patients with atrial fibrillation (AF) and
aortic stenosis (AS) with patients with AF with mitral
regurgitation (MR) or aortic regurgitation (AR) and
patients without significant valve disease (no SVD).
Methods Using Rivaroxaban Once-Daily, Oral, Direct
Factor Xa Inhibition Compared With Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET AF) data, we analysed efficacy and
safety outcomes, adjusting hazard ratios (HRs) for potential
confounders using Cox regression analysis.
Results Among 14 119 intention-to-treat ROCKET AF
trial patients, a trial that excluded patients with mitral
stenosis or artificial valve prosthesis, 214 had AS with or
without other valve abnormalities, 1726 had MR or AR and
12 179 had no SVD. After adjusting for prognostic factors,
the composite of stroke, systemic embolism or vascular
death increased approximately twofold in patients with AS
(AS 10.84, MR or AR 4.54 and no SVD 4.31 events per
100 patient-years, p=0.0001). All-cause death also
significantly increased (AS 11.22, MR or AR 4.90 and no
SVD 4.39 events per 100 patient-years, p=0.0003). Major
bleeding occurred more frequently in AS (adjusted HR 1.61,
confidence intervals (CI) 1.03 to 2.49, p<0.05) and MR or
AR (HR 1.30, 1.07 to 1.57, p<0.01) than in no SVD, but
there was no difference between AS and MR or AR (HR
1.24, 0.78 to 1.97). The relative efficacy of rivaroxaban
versus warfarin was consistent among patients with and
without valvular disease. Rivaroxaban was associated with
higher rates of major bleeding than warfarin in patients
with MR or AR (HR 1.63, 1.15 to 2.31).
Conclusions We found that patients with AF and AS on
oral anticoagulants may have distinctly different efficacy and
safety outcomes than patients with MR or AR or no SVD.
Trial registration number NCT00403767;
Post-results.
INTRODUCTION
The Rivaroxaban Once-Daily, Oral, Direct Factor
Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation (ROCKETAF) study was a
large randomised trial that compared warfarin and
rivaroxaban, a novel factor Xa inhibitor, in patients
with non-valvular AF, defined as the absence of
mitral stenosis or artificial valve prosthesis.1 2 These
criteria allowed for the inclusion of patients with
other valve disease types, representing a heteroge-
neous group with mitral regurgitation (MR), aortic
regurgitation (AR) or aortic stenosis (AS), alone or in
combination.3 The clinical characteristics and out-
comes of patients with AF with valve disease, com-
pared with those without, were recently reported.3
In our retrospective study, we compared the
characteristics and outcomes of patients with
ROCKET AF without valve disease (‘true’ non-
valvular AF) with two subgroups with valve
disease. We hypothesised that patients with AS on
oral anticoagulation might have different outcomes
than patients with MR or AR.
METHODS
We used ROCKET AF data to retrospectively
perform our analysis.1 2 The rationale and design
of ROCKET AF have been previously published
(ClinicalTrials.gov #NCT00403767).1 Our study
differed from the previously published analysis3
since we compared two subgroups of patients with
valve disease with patients with non-valvular AF. If
the recruiting physician considered a lesion to be
significant, then the patient was included in the
group with significant valve disease (SVD). Patients
were excluded if they met clinical criteria for immi-
nent surgical or percutaneous valvular intervention,
therefore excluding those with advanced/high-grade
valvular disease. Patients with SVD were subdivided
into those with AS (if at least one valve location/
abnormality was AS) and those with MR or AR
(table 1), which included patients in whom at least
one valve location/abnormality was MR or AR (but
none was AS). For the purposes of this study, we
analysed patients with: (1) no SVD and subgroups
with SVD, (2) AS and (3) MR or AR.
Among 14 171 intention-to-treat patients, 12 179
had no SVD, whereas 1992 (14.1%) had
investigator-classified SVD. In 52 patients with
SVD, the valve location was unknown; conse-
quently, they were omitted from the current efficacy
analyses, leaving 1940 intention-to-treat patients
with SVD (AS, n=214; MR or AR, n=1726). The
safety population consisted of 14 236, including
1945 patients with SVD with known location,
12 237 without SVD and 54 patients were omitted
for SVD with unknown location.
The primary efficacy endpoint in ROCKET AF
was the composite of all stroke (both ischaemic and
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haemorrhagic) and systemic embolism.1 2 Secondary efficacy
endpoints included stroke; all-cause death; the composite of
stroke, systemic embolism or vascular death; and the composite
of stroke, systemic embolism, vascular death or myocardial
infarction. The primary safety endpoint was major or non-major
clinically relevant bleeding (NMCR); secondary safety endpoints
were major bleeding, gastrointestinal bleeding and intracranial
haemorrhage. All clinical endpoints were adjudicated by a com-
mittee blinded to the treatment assignment.
Statistical analysis
Two populations were used: (1) intention to treat: patients who
were randomised, for baseline summaries and analysis of efficacy
endpoints and (2) on-treatment (or safety): intention-to-treat
patients who received at least one study drug dose, for safety end-
point analysis. The methodology of the present analyses has been
reported3 (see online supplementary material).
Clinical characteristics are presented using medians (with
25th and 75th percentiles) for continuous variables and percent
(frequency) for categorical variables. A single overall test
(Kruskal–Wallis for continuous variables and Pearson χ2 for cat-
egorical) was performed to determine the differences among
the three subgroups.
Event rates (per 100 patient-years and total) were generated
for all endpoints. Cox regression analysis was used to adjust
comparisons for potential confounders.3 Hazard ratios (HRs;
95% confidence intervals (CIs)) and Wald χ2 tests were gener-
ated for all three pairwise comparisons: (1) AS versus MR or
AR; (2) AS versus no SVD and (3) MR or AR versus no SVD.
The efficacy analyses used the intention-to-treat population
and the time period to site notification. The safety endpoint ana-
lyses used the safety population and the on-treatment period (ie,
time to last exposure plus 2 days). The same covariates were used
as reported (3; see online supplementary material). For treatment
comparisons among subgroups, event rates were summarised by
treatment among AS, MR or AR, and no SVD. After adding inter-
action terms AS*rivaroxaban and other-SVD*rivaroxaban, a
single overall test was performed in each model to determine
treatment effect differences among the three groups; if signifi-
cant, then rivaroxaban versus warfarin HRs (95% CI) were gen-
erated for all three subgroups. For each model, the proportional
hazards assumption was tested and found to have been met.
All statistical analyses were performed by the Duke Clinical
Research Institute (Durham, North Carolina, USA) using SAS
software (V.9.2, SAS Institute, Cary, North Carolina, USA).
RESULTS
Clinical characteristics of patients
Tables 1 and 2 show the location of valve disease and clinical
characteristics of 1940 intention-to-treat patients. Compared
with others, patients with AS were older, slightly heavier, less
often had persistent AF, more new onset AF, more peripheral
artery disease, prior myocardial infarction, slightly higher
CHADS2 (C, Congestive heart failure; H, Hypertension; A, Age
≥75 years; D, Diabetes mellitus; S2, prior Stroke or transient
ischaemic attack (TIA) or thromboembolism) score and lower
creatinine clearances.
Efficacy and safety endpoints
Event rates for efficacy and safety outcomes are presented in
figures 1 and 2, table 3 and in online supplementary figures 1
and 2. Stroke or systemic embolism occurred about twice as
often in the AS group (4.21) than in the MR or AR (2.01) or
the no SVD groups (2.09 events/100 patient-years; p<0.05
each), whereas there was no difference between patients with
MR or AR and patients with no SVD. The composite of stroke,
systemic embolism or vascular death was increased approxi-
mately twofold in patients with AS (AS 10.84) compared with
patients with MR or AR (4.54) and patients with no SVD (4.31
events per 100 patient-years, p<0.01 each), whereas again, MR
or AR and no SVD did not differ. All-cause death (AS 11.22,
MR or AR 4.90 and no SVD 4.39 events per 100 patient-years)
and the combined outcome of stroke, systemic embolism and
vascular death (with or without myocardial infarction) occurred
also twice as often in AS than in the other two groups (p<0.01
for each comparison), whereas MR or AR did not differ from
no SVD (table 3B).
Early study drug discontinuation rates were different in the
three groups (AS 58%, MR or AR 40% and no SVD 34%).
However, patterns of stroke rates in the per-protocol
on-treatment population were not markedly different from
those in intention-to-treat patients (table 3A).
Major bleeding (figure 2 and table 3B, see online supplementary
figure S2) occurred more frequently in AS (7.61) than in no SVD
(3.27 events/100 patient-years; adjusted HR 1.61, CI 1.03 to
2.49, p<0.05). In patients with MR or AR, the risk of major
bleeding was also significantly higher (4.86 events/100 patient-
years) than in no SVD (adjusted HR 1.30, CI 1.07 to 1.57,
p<0.01), whereas the difference between AS and MR or AR did
not reach significance (adjusted HR 1.24, CI 0.78 to 1.97). Major
clinically relevant and NMCR bleeding occurred more often in AS
(24.36), less often in MR or AR (17.66) and was lowest in no SVD
(14.16 events/100 patient-years). However, only the difference
between MR or AR and no SVD reached significance (p<0.05).
Gastrointestinal bleeding rates were numerically higher in AS and
MR or AR, but statistically different only for MR or AR versus no
SVD (p<0.05). Intracranial haemorrhage occurred rarely and did
not differ among groups (table 3B).
Treatment comparisons for efficacy and safety endpoints
There were no significant interactions among patients rando-
mised to rivaroxaban and warfarin, indicating a consistent risk
relationship between rivaroxaban and warfarin across the three
subgroups for all efficacy endpoints (see online supplementary
table S1). For the major or NMCR bleeding and major bleeding
outcomes, the interaction tests were significant (figure 3, see
online supplementary table S1). In patients without SVD, rivar-
oxaban and warfarin had a neutral relationship (HRs very close
to 1), while patients with MR or AR had an elevated risk of
Table 1 Location of valvular disease in those 1940 randomised
ITT patients in whom information on the location of diseased valves
was available
Type of valve disease N
Aortic stenosis (n=214)
Isolated aortic stenosis 87
Plus mitral regurgitation 59
Plus aortic regurgitation 18
Plus mitral and aortic regurgitation 50
Mitral or aortic regurgitation (n=1726)
Isolated mitral regurgitation 1309
Mitral and aortic regurgitation 329
Isolated aortic regurgitation 88
ITT, intention to treat.
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either of these two bleeding categories with rivaroxaban com-
pared with warfarin (HR 1.32 and 1.63, respectively). Patients
with AS also had HRs of 1.18 and 1.73, but the CIs were wide,
reaching 1.0. There was no significant interaction for gastrointes-
tinal bleeding, and there were too few intracranial haemorrhages
to draw any conclusions (see online supplementary table S1).
DISCUSSION
In ROCKET AF, 14.1% of patients had SVD that did not meet
mitral stenosis and artificial valve prostheses exclusion criteria3;
these patients were older and had more comorbidities than
those without SVD, similar to preliminary data from the
Randomised Evaluation of Long Term Anticoagulant Therapy
(RE-LY) and Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
trials.4–6 In ROCKET AF, the rates of stroke or systemic embol-
ism were comparable among patients with and without SVD,
whereas the rates of major or NCMR or major bleeding alone
were higher in patients with SVD,3 similar to findings from
ARISTOTLE4 5 and RE-LY.4 6 In patients with SVD allocated to
rivaroxaban, the rates of major and NMCR or major bleeding
alone were higher than in warfarin patients compared with
no-SVD patients. However, there was no difference between
both treatment arms after controlling for risk factors and poten-
tial confounders. For intracranial haemorrhage, there was no
interaction between patients with and without SVD where the
overall rate was lower among those randomised to rivaroxaban.3
Our patients with SVD3 were older (median 75 vs 71 years),
had higher CHADS2 scores (mean 3.5 vs 2.2) and had more fre-
quently prior stroke, systemic embolism or TIA (48.2% vs
18.8%) than patients with valvular heart disease in
ARISTOTLE.5
Preliminary data for our retrospective exploratory analysis
were recently presented.7 Here, we present a detailed analysis of
Table 2 Baseline clinical characteristics for all ITT patients with known location of valve disease grouped by the three patient subgroups
Variable AS* (n=214) MR or AR* (n=1726) No SVD* (n=12 179) p Value†
Age 78 (73, 82) 74 (67, 79) 72 (65, 78) <0.0001
Female 37% (79) 40% (682) 40% (4820) 0.73
Atrial fibrillation 0.0082
Persistent 79% (170) 83% (1435) 81% (9832)
Paroxysmal 17% (37) 16% (277) 18% (2173)
New onset 3% (7) 1% (14) 1% (174)
CHADS2 score (mean (SD)) 3.6 (0.9) 3.5 (1.0) 3.5 (0.9) 0.053
CHADS2 score
2 8% (18) 14% (247) 13% (1585)
3 42% (89) 43% (743) 44% (5311)
4 33% (70) 27% (467) 29% (3521)
5 14% (30) 13% (230) 13% (1532)
6 3% (7) 2% (39) 2% (230)
HAS-BLED score (mean (SD)) 3.0 (0.9) 2.8 (1.0) 2.8 (0.9) 0.0005
Presenting characteristics
BMI, kg/m2 29 (26, 32) 28 (25, 31) 28 (25, 32) <0.0001
Systolic BP, mm Hg 130 (120, 142) 130 (120, 140) 130 (120, 140) <0.0001
Diastolic BP, mm Hg 78 (70, 85) 80 (70, 85) 80 (70, 86) <0.0001
Creatinine clearance,‡ ml/min 61 (44, 78) 63 (49, 80) 68 (53, 88) <0.0001
Baseline comorbidities
Prior stroke, TIA or non-CNS embolism 46% (99) 48% (829) 56% (6806) <0.0001
PAD 15% (32) 7% (124) 6% (672) <0.0001
Hypertension 92% (197) 89% (1542) 91% (11 049) 0.14
Diabetes 43% (92) 40% (690) 40% (4849) 0.64
Prior MI 30% (64) 23% (404) 16% (1964) <0.0001
Congestive HF 65% (139) 71% (1228) 61% (7449) <0.0001
COPD 19% (40) 14% (243) 10% (1194) <0.0001
Medications
Prior vitamin K antagonist use 74% (158) 72% (1251) 61% (7409) <0.0001
Prior chronic ASA use 37% (80) 34% (589) 37% (4494) 0.079
ACE-inhibitor/ARB at baseline 78% (167) 76% (1306) 74% (9029) 0.18
β blocker at baseline 65% (140) 71% (1225) 64% (7789) <0.0001
Digitalis at baseline 41% (88) 44% (754) 38% (4589) <0.0001
Diuretic at baseline 75% (160) 70% (1212) 58% (7031) <0.0001
Randomised to rivaroxaban 49% (105) 48% (834) 50% (6119) 0.32
All other abbreviations can be found in table 1.
*Continuous variables are shown as median (25th, 75th percentile) except where noted, and categorical variables as % (n).
†p Values are for any differences across groups.
‡Cockroft-Gault.
A, Age ≥75 years; ARB, angiotensin receptor blocker; AS, aortic stenosis; ASA, acetylsalicylic acid, aspirin; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile international normalized ratio, elderly (> 65 years), drugs/alcohol concomitantly; BMI, body mass index; BP, blood pressure; CHADS2, C, congestive
heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; D, diabetes mellitus; H, hypertension; HF, heart failure; MI, myocardial infarction; MR or AR,
mitral or aortic regurgitation; PAD, peripheral artery disease; S2, prior Stroke or TIA or thromboembolism; SD, standard deviation; SVD, significant valve disease; TIA, transient ischaemic
attack; R, rivaroxaban; W, warfarin.
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valve disease subgroups in patients with non-valvular AF treated
with oral anticoagulation.
Clinical characteristics
Due to protocol inclusion and exclusion criteria,1 2 patients with
AS suffered moderate-to-intermediate aortic lesions since severe
lesions requiring imminent intervention were excluded. The
majority of patients in the AS group (59%) also had MR or AR
(table 1). No reasonable comparison can be made between our
patients (who constitute a special group, all with AF requiring
anticoagulation for the prevention of stroke or systemic embolism)
with other reports.8–12 These reports either included patients with
aortic valve sclerosis,8 or AS without any anticoagulation,9 or
patients with MR selected on the basis of left ventricular dysfunc-
tion who had a low prevalence of AF of 8–11%10 or 8.8–16.3%11
without any information on oral anticoagulation or no informa-
tion on the prevalence of AF or oral anticoagulation.12
Efficacy outcomes
Our analysis suggests that secondary endpoints, including all-
cause death, were significantly higher among AS patients,
despite AS being of moderate or intermediate severity. Also,
stroke and systemic embolism (the primary outcome parameter)
occurred about twice as often in patients with AS compared
with those without (table 3).
Clinical outcomes like stroke, systemic embolism or death
among patients with valvular disease subtypes treated with oral
anticoagulation have not been well established. The association
between AS and stroke is controversial.13–16 The need for oral
anticoagulation in patients with AS is generally not mentioned
in valvular heart disease guidelines,14 17 except when AF is
present.
The rate of stroke in the AS group with AF on oral anticoagu-
lation was high (3.68/100 patient-years) in comparison with the
Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial in
which patients in the early phase of disease were selected for
drug intervention (0.56/100 patient-years).9 SEAS only included
patients not on oral anticoagulation; only 6.4% had AF. SEAS
patients had mild-to-moderate AS (presumably similar in sever-
ity to our patients), but a much lower stroke risk, which corre-
lated to a low CHA2DS2-VASc (C, congestive heart failure; H,
hypertension; A, age ≥75 years; D, diabetes mellitus; S2, prior
Stroke or TIA or thromboembolism; V, vascular disease; A, age
65–74 years; SC, sex category (female)) score of 1.8±1.2.9 In
our study, patients were markedly older (78 median vs 67.3
±9.7 years), and all had AF and a 3.6 CHADS2 score (median).
Figure 1 Efficacy endpoints by SVD
subtype and for patients with no SVD
based on ITT patients. Efficacy
endpoints (events per 100
patient-years, unadjusted) by SVD
subtype and for patients with no SVD
based on ITT patients. p Values for any
difference among groups are based on
Cox proportional hazards models.
Patients in both treatment arms are
combined. For results of detailed
statistical analyses, see table 3. ITT,
intention to treat; MI, myocardial
infarction; pt-years, patient-years; SE,
systemic embolism; SVD, significant
valve disease; MR or AR, mitral or
aortic regurgitation; vasc. death,
vascular death.
Figure 2 Safety endpoints by SVD
subtype and for patients with no SVD.
Safety endpoints (events per 100
patient-years, unadjusted) by SVD
subtype and for patients with no SVD.
p Values for any difference among
groups are based on Cox proportional
hazards models. Patients in both
treatment arms are combined. For
results of detailed statistical analyses,
see table 3. NMCR, non-major
clinically relevant; pt-years, patient
years; SVD, significant valve disease;
MR or AR, mitral or aortic
regurgitation.
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Therefore, the higher rate of stroke and systemic embolism in
our cohort compared with SEAS9 may be explained by the pres-
ence of AF, older age and other risk factors impacting the stroke
risk score.
In a study from Olmsted County,18 22% of patients with AS
experienced a cerebrovascular event during 7-year follow-up
(adjusted yearly risk 3.1%), which seems comparable to
ROCKET AF. Yet, the Olmsted County analysis excluded sys-
temic embolism and included patients with severe AS (39% of
cases); 48% received oral anticoagulation. Following adjustment
for age and AF, severe AS (compared with moderate) was asso-
ciated with an increased risk of cerebrovascular events (risk ratio
5.35, 95% CI 1.4 to 8.6).18
The death rate in patients with AS was about twice as high as
those with MR or AR and no SVD (p<0.01 each). In the
Olmsted County study,18 patients with AS had increased mortal-
ity (57% at 5 years; 71% at 7 years), which is not too different
from our death rate (11.22/100 patient-years) when compared
with their 5-year and 7-year rates. Nevertheless, as previously
noted, the Olmsted County study also included patients with
severe AS, who have a 50% 1-year mortality rate.
MR was the dominant diagnosis in the MR or AR group. The
risk of stroke or systemic embolism in patients with MR or AR
was comparable with no SVD. Some reports suggest that
patients with AF with MR have lower rates of left atrial thrombi
intra-operatively19 20 or on echocardiography21 than those
without MR. Some suggest a reduced propensity to thrombo-
embolism in patients with MR and AF,22–24 although other
studies failed to show a similar beneficial effect of MR.25 In
patients with non-rheumatic AF, Miyasaka et al24 observed the
highest prevalence of thromboembolism (28%) in those with
grade 1 MR, whereas those with grade >2 (8%, p=0.006) and
with none had the lowest event rates (11%, p=0.007). Platelet
activation due to MR may enhance the formation of platelet–
fibrin thrombus on the mitral leaflet, thereby increasing
embolisation.26
In contrast to some of the reports mentioned above, we could
not confirm a reduced thromboembolism rate in our patients
with MR compared with no SVD.
Safety outcomes
Current literature lacks detailed analyses of bleeding in valve
disease patients taking oral anticoagulants to prevent stroke. In
our study, patients with AS had the highest risk of major bleed-
ing in comparison with patients with no SVD (p<0.05) but not
significantly higher compared with patients with MR or AR.
The latter patients also had a significantly higher rate of major
bleeding than patients with no SVD (p<0.01).





MR or AR events/100 pt-years
(CI) (total events)
No SVD events/100 pt-years
(CI) (total events)
Efficacy outcomes
Stroke or SE 4.21 (1.89 to 6.53) (17) 2.01 (1.50 to 2.52) (69) 2.09 (1.89 to 2.29) (487)
Stroke, SE, or vascular death 10.84 (7.23 to 14.45) (41) 4.54 (3.78 to 5.30) (152) 4.31 (4.03 to 4.59) (982)
Stroke, SE, vascular death, or MI 12.09 (8.25 to 15.93) (45) 5.72 (4.86 to 6.58) (189) 4.99 (4.68 to 5.30) (1128)
Stroke 3.68 (1.52 to 5.84) (15) 1.71 (1.24 to 2.18) (59) 1.96 (1.77 to 2.15) (458)
Early study drug discontinuation (%)* 58.4 (51.5 to 65.1) (125) 39.6 (37.3 to 41.9) (685) 34.0 (33.2 to 34.8) (4161)
Stroke per-protocol on-treatment* 4.30 (1.81 to 6.79) (12) 1.50 (1.04 to 1.96) (39) 1.90 (1.70 to 2.10) (354)
All-cause death 11.22 (7.65 to 14.79) (43) 4.90 (4.12 to 5.68) (164) 4.39 (4.11 to 4.67) (1002)
Safety outcomes
Major or NMCR bleeding 24.36 (18.14 to 30.58) (59) 17.66 (15.98 to 19.34) (422) 14.16 (13.60 to 14.72) (2431)
Major bleeding 7.61 (4.35 to 10.87) (21) 4.86 (4.03 to 5.69) (131) 3.27 (3.01 to 3.53) (625)
Gastrointestinal bleeding 2.90 (0.89 to 4.91) (8) 2.12 (1.57 to 2.67) (57) 1.32 (1.16 to 1.48) (252)
Intracranial haemorrhage 1.40 (0.03 to 2.77) (4) 0.76 (0.43 to 1.09) (21) 0.59 (0.48 to 0.70) (114)
(B) Group comparisons
Outcomes
AS vs No SVD
HR (CI)
AS vs MR or AR
HR (CI)
MR or AR vs no SVD
HR (CI)
Efficacy outcomes
Stroke or SE 1.82 (1.10 to 3.01)* 1.87 (1.08 to 3.23)* 0.97 (0.75 to 1.26)
Stroke, SE or vascular death 2.03 (1.47 to 2.79)** 2.12 (1.49 to 3.01)** 0.96 (0.80 to 1.14)
Stroke, SE, vascular death or MI 1.91 (1.41 to 2.59)** 1.84 (1.32 to 2.56)** 1.04 (0.88 to 1.21)
Stroke 1.70 (1.00 to 2.92)* 1.93 (1.07 to 3.46)* 0.88 (0.67 to 1.16)
All-cause death 1.88 (1.38 to 2.56)** 1.94 (1.38 to 2.72)** 0.97 (0.82 to 1.15)
Safety outcomes
Major or NMCR bleeding 1.28 (0.98 to 1.66) 1.14 (0.87 to 1.51) 1.12 (1.00 to 1.24)*
Major bleeding 1.61 (1.03 to 2.49)* 1.24 (0.78 to 1.97) 1.30 (1.07 to 1.57)**
Gastrointestinal bleeding 1.39 (0.68 to 2.83) 1.04 (0.49 to 2.18) 1.34 (1.00 to 1.80)*
Intracranial haemorrhage 2.04 (0.75 to 5.60) 1.63 (0.55 to 4.77) 1.26 (0.79 to 2.01)
*Although early study drug discontinuation rates were different in the three groups, event rates for stroke were not markedly different between on-treatment and ITT patients.
Event rates are underadjusted.
p Values for group comparisons: *p<0.05, **p<0.01.
AS, aortic stenosis; CI, confidence interval; ITT, intention to treat; MI, myocardial infarction; MR or AR, mitral or aortic regurgitation; NMCR, non-major clinically relevant; pt-years,
patient-years; SE, systemic embolism; SVD, significant valve disease.
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Our major bleeding rate of 3.27 events per 100 patient-years
in patients with no SVD (table 3) is close to real-world data from
a pharmacovigilance study of rivaroxaban with non-valvular AF
that excluded patients with any type of valve disease. In this
study of 27 467 patients, the incidence of major bleeding was
2.86 per 100 person-years (95% CI 2.61 to 3.13).27 CHADS2
scores were 3.0 for those with major bleeding and 2.2 for those
without; these scores are lower than those in our population.
Mechanisms of thromboembolism and of bleeding in
valvular disease
Potential mechanisms for systemic embolism in AS include
increased mean platelet volume,28 increased platelet production
indices in aortic valve sclerosis patients29 and turbulent flow with
subsequent activation of coagulation and platelets.30 Minimally
calcified aortic valves have proven to exhibit anti-aggregatory
effects, whereas AS does not demonstrate these same effects.31 In
addition to a possible prothrombotic effect, other phenomena
observed in patients with AS demonstrate evidence of impaired
haemostasis with a decrease in von Willebrand factor.32
Concomitant AF further complicates the picture since AF is con-
sistently related to higher levels of von Willebrand factor than in
AF’s absence.33–36 Consequently, there may be opposing distur-
bances in the coagulation system due to the AS/AF combination.
We observed an increased bleeding risk in patients with AS,
which was more pronounced on rivaroxaban than warfarin; if
this is not a chance finding, then it is of clinical importance and
needs further corroboration, yet our data do not explain the
mechanisms behind the potentially higher bleeding rate in
patients with AS.
Bleeding in patients with AS has been related to gastrointes-
tinal angiodysplasia (ie, Heyde’s syndrome),37–40 which is asso-
ciated with acquired type 2A von Willebrand syndrome
(characterised by the loss of the largest multimers of von
Willebrand factor).41 42 Shear stress ex vivo enhances the prote-
olysis of von Willebrand factor in normal plasma.42 Vincentelli
et al32 found von Willebrand factor abnormalities to be directly
related to the stenosis severity; furthermore, they could be
reversed by aortic valve replacement if there was no implanted
prosthesis mismatch.32 43–46
Effect of type of anticoagulation
For efficacy outcomes, there were no significant interactions
since the interaction tests between treatment and SVD group
were non-significant; therefore, the risk relationship between
rivaroxaban and warfarin was consistent across SVD subgroups.
HRs from the full ROCKET AF cohort2 are the best estimate of
treatment effects.
Interaction tests for between-treatment bleeding suggested a
significant difference when comparing the three subgroups. In
patients without SVD, rivaroxaban and warfarin had a neutral
relationship (HR close to 1.0), whereas those with MR or AR
had an elevated risk of any bleeding (except for intracranial
haemorrhage) with rivaroxaban compared with warfarin.
Patients with AS also had higher HR for rivaroxaban versus war-
farin, which was especially pronounced for major bleeding (this
difference did not reach statistical significance; CIs were below
and above 1.0). There was a tendency towards higher rates of
gastrointestinal bleeding in patients with AS and MR or AR.
There were too few intracranial haemorrhages to draw any
conclusions.
Our study had several limitations. First, although we exam-
ined a large trial population, the proportion of patients with
moderate or intermediate AS severity was relatively small.
Second,3 the protocol did not include a precise quantification of
valve disease, so the two SVD subgroups do not represent iso-
lated disease types (eg, patients in the AS group also had regur-
gitant lesions). Third, our data do not allow any balance
estimate between AS severity and other lesions (if present).
Finally, the relatively low number of cases, especially in those
with AS, reduces the chance of finding true differences.
Therefore, conclusions regarding treatment effects should be
drawn cautiously. More studies are needed to better understand
the thromboembolic event-related clinical characteristics and
outcomes in patients with valvular disease (after exclusion of
mitral stenosis or artificial valves).
CONCLUSIONS
Our retrospective exploratory analysis of ROCKET AF found
that among patients with AF treated with oral anticoagulation
(either rivaroxaban or warfarin), AS stood out from other groups
with regard to efficacy endpoints (eg, stroke, systemic embolism
and vascular death); in patients with other valve disease (MR or
AR) and non-valve disease (no SVD), these endpoints did not
differ. Major bleeding rates increased from no SVD to MR or AR
to AS. Oral anticoagulation type did not cause a difference in effi-
cacy outcomes, but bleeding occurred more frequently in patients
with AS and other types of valve disease randomised to
Figure 3 Treatment comparisons
between patients allocated to
rivaroxaban and warfarin. Treatment
comparisons between patients
allocated to rivaroxaban and warfarin
for safety endpoints among SVD
subtypes and for patients with no SVD.
Events per 100 patient-years,
unadjusted. p Values for any difference
among groups are based on Cox
proportional hazards models. Patients
in each treatment are shown
separately. For results of detailed
statistical analyses, see online
supplementary table S1. NMCR,
non-major clinically relevant; pt-years,
patient years; SVD, significant valve
disease; MR or AR, mitral or aortic
regurgitation.
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rivaroxaban rather than warfarin (although the difference missed
significance). There was no difference in the no SVD group
between treatment allocation. We believe our study is the first to
suggest that in patients with AF who mainly have AS treated with
oral anticoagulation, the efficacy and safety outcomes may be dif-
ferent from those with MR or AR (predominantly MR) or no
SVD. This notion may be intuitive, but has not been demon-
strated in a patient population selected for AF presence.
Key messages
What is already known on this subject?
Current literature is lacking detailed analyses of various types of
valve disease (after exclusion of patients with mitral stenosis or
artificial prostheses) in the presence of atrial fibrillation with
regard to systemic embolism and bleeding when a patient is on
warfarin or rivaroxaban for stroke prevention.
What might this study add?
In this first detailed analysis of subgroups with valve disease,
the composite of stroke, systemic embolism or vascular death
was about twofold higher in aortic stenosis (AS) than in mitral
or aortic regurgitation or no valve disease. Major bleeding
occurred more frequently in AS than in the other two groups.
For efficacy endpoints comparing rivaroxaban and warfarin,
there were no significant treatment interactions but for bleeding
outcomes, the interaction tests were significant.
How might this impact on clinical practice?
We found that patients with atrial fibrillation and AS who are
being treated with oral anticoagulation have efficacy and safety
outcomes that are distinctly different from patients with other
types or without any significant valve disease; this finding
should encourage clinicians to carefully consider the risks of
thromboembolic complications versus bleeding especially in
patients with AS.
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